Colonic graft-versus-host disease.

Area of Science:

• Hematology
• Immunology
• Gastroenterology

Background:

• Allogeneic hematopoietic stem cell transplantation carries the risk of graft-versus-host disease (GVHD).
• Gastrointestinal GVHD, particularly involving the colon, presents significant management challenges in transplant recipients.
• Understanding the pathogenesis of GVHD is crucial for improving patient outcomes.

Purpose of the Study:

• To provide an updated review on the diagnosis and management of colonic GVHD.
• To highlight current therapeutic strategies and identify areas for future research.

Main Methods:

• Review of current literature on GVHD pathogenesis, diagnosis, and treatment.
• Analysis of diagnostic methods including endoscopic biopsy.
• Evaluation of first-line and refractory treatment options.

Main Results:

• GVHD development is linked to proinflammatory cytokines and T-cell activation against host antigens.
• Acute GVHD commonly affects the skin, liver, and gastrointestinal tract, presenting with symptoms like diarrhea and abdominal pain.
• Endoscopic biopsy is diagnostic, but carries risks in critically ill patients; apoptosis is a key diagnostic feature but not specific.
• Systemic steroids are the primary treatment; infliximab or budesonide are options for steroid-refractory cases, especially with GI involvement.
• Chronic GVHD of the gut is not considered a major factor.

Conclusions:

• Colonic GVHD diagnosis is established, but advances in management depend on a deeper understanding of its pathogenesis.
• Development of more targeted therapies is essential for improving treatment efficacy and patient survival.